Development of a non-viral gene editing platform to generate tumor specific engineered T cells

The generation of tumor specific T cells relies on the use of viral vectors to introduce a transgene to the T-cell's genome. The downside to this technology is that it is time consuming, expensive and the integration site is semi-random. To overcome these challenges, genetic engineering of T cells by means of gene editing as a non-viral platform to introduce the DNA template serves as a promising tool, mitigating the homology-direct repair (HDR) system of the cell. The aim of the project is to develop a non-viral site-specific gene editing approach for the production tumor specific engineered T cells followed by subsequent in vitro analysis of their anti-tumor reactivity.

Contact 
Dorine de Bont